Maura L. Gillison, MD, PhD

Peer-Reviewed Articles

1. Wotman, MT, Xiao, W, Du, R, Jiang, B, Akagi, K, Liu, S, Gillison, M. Development and Validation of an Assay to Quantify Plasma Circulating Tumor Human Papillomavirus DNA for 13 High-Risk Types that Cause 98% of HPV-Positive Cancers. Head and Neck Pathology 19(1), 2025. e-Pub 2025. PMID: 39998590.
2. Galloway, TJ, Pugh, S, Ridge, JA, Nguyen-Tân, PF, Rosenthal, D, Gillison, M, Garden, AS, Dunlap, NE, Caudell, JJ, Jones, CU, Bauman, J, Bahig, H, Shenouda, G, Currey, A, Koyfman, SA, Stokes, WA, Read, NE, Lyness, JA, Yom, SS, Le, Q. Long-Term Feeding Tube Use in Head and Neck Cancer Survivors—An Analysis of Patient- and Treatment-Related Factors. International Journal of Radiation Oncology Biology Physics 123(3):703-712, 2025. e-Pub 2025. PMID: 40473230.
3. Vogtmann, E, Yano, Y, Shi, J, Wan, Y, Purandare, V, McLean, J, Li, S, Knight, R, Kahle, L, Hullings, AG, Hua, X, Graubard, BI, Gillison, M, Caporaso, JG, Bokulich, NA, Blaser, MJ, Freedman, ND, Chaturvedi, A, Abnet, CC. The Oral Microbiome and All-Cause Mortality in a US Population-Representative Prospective Cohort. Journal of Infectious Diseases 232(4):790-795, 2025. e-Pub 2025. PMID: 40513117.
4. Khan, NI, Akagi, K, Jiang, S, Dunn, J, Jiang, B, Xiao, W, O’Hara, MP, Shen, L, Wang, Q, Mohanty, V, Wang, J, Goodwin, S, Hutchins, JL, Coombes, KR, Sastry, JK, Symer, DE, Gillison, M. Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers. Cancer discovery 15(9):1927-1948, 2025. e-Pub 2025. PMID: 40358390.
5. Jiang, XL, Rudqvist, N, Jiang, B, Ye, S, He, S, Liang, Q, Dou, J, Williams, MD, Dunn, J, Johnson, JM, Akagi, K, Xiao, W, Liang, S, Elayavalli, S, Sun, B, Parra Cuentas, ER, Ferrarotto, R, Garden, AS, Fuller, C, Reddy, JP, Gross, N, Lango, MN, Leung, CH, Liu, S, Liu, D, Li, M, Lee, JJ, Curran, M, Phan, J, Chen, K, Gillison, M. Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade. Cancer discovery 15(8):1569-1592, 2025. e-Pub 2025. PMID: 40249124.
6. Chaturvedi, A, Vogtmann, E, Shi, J, Yano, Y, Blaser, MJ, Bokulich, NA, Caporaso, JG, Gillison, M, Graubard, BI, Hua, X, Hullings, AG, Kahle, L, Knight, R, Li, S, McLean, J, Purandare, V, Wan, Y, Freedman, ND, Abnet, CC. Oral Microbiome Profile of the US Population. JAMA Network Open 8(5), 2025. e-Pub 2025. PMID: 40323603.
7. DSouza, G, Tewari, SR, Troy, T, Bleyer, P, Korley, M, Kwait, J, Ho, K, Gillison, M, Wiley, D, Lazar, J, Weber, K, Strickler, HD, Lahiri, CD, Palella, F, Struijk, L, Fakhry, C. Oral HPV incidence and risk factors for acquisition. Oral Oncology 163, 2025. e-Pub 2025. PMID: 40101427.
8. Moreno Rueda LY, Wang H, Akagi K, Dang M, Vora A, Qin L, Lee HC, Patel KK, Lin P, Mery DE, Zhan F, Shaughnessy JD Jr, Yi Q, Song Y, Jiang B, Gillison ML, Thomas SK, Weber DM, Diao L, Wang J, Kuiatse I, Manasanch EE, Symer DE, Orlowski RZ. Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets. Cell Rep Med 6(2):101925, 2025. e-Pub 2025. PMID: 39855192.
9. Seo A, Xiao W, Gjyshi O, Yoshida-Court K, Wei P, Swanson D, Cisneros Napravnik T, Grippin A, Venkatesan AM, Jacobsen MC, Fuentes DT, Lynn E, Sammouri J, Jhingran A, Joyner M, Lin LL, Colbert LE, Gillison ML, Klopp AH. Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation. Clin Cancer Res 31(4):697-706, 2025. e-Pub 2025. PMID: 39680029.
10. Landy R, Haber GW, Graubard BI, Fakhry C, Campos NG, Burger EA, Cheung LC, Katki HA, Gillison ML, Chaturvedi AK. Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study. J Natl Cancer Inst 117(6):1209-1217, 2025. e-Pub 2025. PMID: 39913364.
11. Johnson FM, O'Hara MP, Yapindi L, Jiang P, Tran HT, Reuben A, Xiao W, Gillison ML, Sun X, Khalaf A, Lee JJ, Sastry JK, Ghosh S. Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas. Clin Cancer Res 31(3):479-490, 2025. e-Pub 2025. PMID: 39589337.
12. Colevas AD, Cmelak AJ, Pfister DG, Spencer S, Adkins D, Birkeland AC, Brizel DM, Busse PM, Caudell JJ, Durm G, Fakhry C, Galloway T, Geiger JL, Gillison ML, Glastonbury C, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Juloori A, Kase M, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Price K, Rocco JW, Rodriguez CP, Schwartz D, Shah JP, Sher D, John MS, Wang H, Weinstein G, Worden F, Bruce JY, Yom SS, Zhen W, Montgomery S, Darlow SD. NCCN Guidelines(R) Insights: Head and Neck Cancers, Version 2.2025. J Natl Compr Canc Netw 23(2):2-11, 2025. e-Pub 2025. PMID: 39938471.
13. Morris VK, Xiao W, Lin K, Wong CW, Wotman MT, Holliday EB, Huey RW, Noticewala SS, Ludmir EB, Bent AH, Ludford K, Messick C, Koay EJ, Smith G, Konishi T, Bednarski B, Chang GJ, Koong AC, You YN, Das P, Gillison ML. Time dependency for human papillomavirus circulating tumor DNA detection after chemoradiation as a prognostic biomarker for localized anal cancer. Clin Cancer Res 31(12):2399-2405, 2025. e-Pub 2025. PMID: 39873618.
14. Colevas AD, Talebi Z, Winters E, Even C, Lee VH, Gillison ML, Khan SA, Lu R, Pinsky BA, Soldan SS, Vladmirova O, Lieberman PM, Messick TE. First-in-Human clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies. Clin Cancer Res 31(5):815-823, 2025. e-Pub 2025. PMID: 39831818.
15. Machiels, JP, Fayette, J, Haddad, RI, Adkins, D, Gillison, M, Harrington, K, Kim, SB, Le Tourneau, C, Psyrri, A, Rosenberg, AJ, Siu, LL, Tahara, M, William Jr, WN, Ford, J, Jauhari, S, Pyle, R, Shen, YM, Yao, D, Zohren, F, Vokes, EE. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncology 21(16):2007-2016, 2025. e-Pub 2025. PMID: 40511820.
16. Chaturvedi AK, Vogtmann E, Shi J, Yano Y, Blaser MJ, Bokulich NA, Caporaso JG, Gillison ML, Graubard BI, Hua X, Hullings AG, Kahle L, Knight R, Li S, McLean J, Purandare V, Wan Y, Freedman ND, Abnet CC. The mouth of America: the oral microbiome profile of the US population. medRxiv, 2024. e-Pub 2024. PMID: 39677463.
17. Vogtmann E, Yano Y, Shi J, Wan Y, Purandare V, McLean J, Li S, Knight R, Kahle L, Hullings AG, Hua X, Graubard BI, Gillison ML, Caporaso JG, Bokulich NA, Blaser MJ, Freedman ND, Chaturvedi AK, Abnet CC. The oral microbiome and all-cause mortality in the US population. medRxiv, 2024. e-Pub 2024. PMID: 39677439.
18. He, S, Gubin, M, Rafei, H, Basar, R, Dede, M, Jiang, XL, Liang, Q, Tan, Y, Kim, KH, Gillison, M, Rezvani, K, Peng, W, Haymaker, CL, Hernandez, S, Solis Soto, LM, Mohanty, V, Chen, K. Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles. iScience 27(6), 2024. e-Pub 2024. PMID: 38957791.
19. Seiwert, T, Wildsmith, S, Fayette, J, Harrington, K, Gillison, M, Ahn, MJ, Takahashi, S, Weiss, J, Machiels, JP, Baxi, S, Baker, V, Evans, B, Morsli, N, Jill Walker, Real, K, L’Hernault, A, Psyrri, A. Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma. Cancer Immunology, Immunotherapy 73(4), 2024. e-Pub 2024. PMID: 38430375.
20. D’Souza, G, Tewari, SR, Troy, T, Webster-Cyriaque, J, Wiley, D, Lahiri, CD, Palella, F, Gillison, M, Strickler, HD, Struijk, L, Waterboer, T, Ho, K, Kwait, J, Lazar, J, Weber, K, Fakhry, C. Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years. Cancer Epidemiology Biomarkers and Prevention 33(4):OF1-OF9, 2024. e-Pub 2024. PMID: 38294704.
21. Gharzai, LA, Morris, E, Suresh, K, Nguyen-Tân, PF, Rosenthal, D, Gillison, M, Harari, PM, Garden, AS, Koyfman, SA, Caudell, JJ, Jones, CU, Mitchell, DL, Krempl, GA, Ridge, JA, Gensheimer, MF, Bonner, JA, Filion, EJ, Dunlap, NE, Stokes, WA, Le, Q, Torres-Saavedra, P, Mierzwa, ML, Schipper, MJ. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx. The lancet oncology 25(3):366-375, 2024. e-Pub 2024. PMID: 38423050.
22. Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Å B, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. JAMA Oncol 9(6):779-789, 2023. e-Pub 2023. PMID: 37022706.
23. Chaturvedi, A, Engels, EA, Pfeiffer, RM, Hernandez, BY, Xiao, W, Kim, E, Jiang, B, Goodman, MT, Sibug-Saber, M, Cozen, W, Liu, L, Lynch, CF, Wentzensen, N, Jordan, RC, Altekruse, S, Anderson, WF, Rosenberg, PS, Gillison, M. Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. Journal of Clinical Oncology 41(17):3081-3088, 2023. e-Pub 2023. PMID: 37285653.
24. Chu, Y, Dai, E, Li, Y, Han, G, Pei, G, Ingram, D, Thakkar, K, Qin, JJ, Dang, M, Le, X, Hu, C, Deng, Q, Sinjab, A, Gupta, P, Wang, R, Hao, D, Peng, F, Yan, X, Liu, Y, Song, S, Zhang, S, Heymach, JV, Reuben, A, Elamin, YY, Pizzi, MP, Lu, Y, Segura Lazcano, R, Hu, J, Li, M, Curran, M, Futreal, A, Maitra, A, Jazaeri, AA, Ajani, JA, Swanton, C, Cheng, XD, Abbas, HA, Gillison, M, Bhat, KP, Lazar, A, Green, M, Litchfield, K, Kadara, HN, Yee, C, Wang, L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nature medicine 29(6):1550-1562, 2023. e-Pub 2023. PMID: 37248301.
25. Xi Y, Negrao MV, Akagi K, Xiao W, Jiang B, Warner SC, Dunn JD, Wang J, Symer DE, Gillison ML. Noninvasive genomic profiling of somatic mutations in oral cavity cancers. Oral Oncol 140:106372, 2023. e-Pub 2023. PMID: 37004423.
26. Goyal N, Hennessy M, Lehman E, Lin W, Agudo A, Ahrens W, Boccia S, Brennan P, Brenner H, Cadoni G, Canova C, Chen C, Conway D, Curado MP, Dal Maso L, Daudt AW, Edefonti V, Fabianova E, Fernandez L, Franceschi S, Garavello W, Gillison M, Hayes RB, Healy C, Herrero R, Holcatova I, Kanda JL, Kelsey K, Hansen BT, Koifman R, Lagiou P, La Vecchia C, Levi F, Li G, Lissowska J, Mendoza López R, Luce D, Macfarlane G, Mates D, Matsuo K, McClean M, Menezes A, Menvielle G, Morgenstern H, Moysich K, Negri E, Olshan AF, Pandics T, Polesel J, Purdue M, Radoi L, Ramroth H, Richiardi L, Schantz S, Schwartz SM, Serraino D, Shangina O, Smith E, Sturgis EM, Swiatkowska B, Thomson P, Vaughan TL, Vilensky M, Winn DM, Wunsch-Filho V, Yu GP, Zevallos JP, Zhang ZF, Zheng T, Znaor A, Boffetta P, Hashibe M, Lee YA, Muscat JE. Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium. Oral Dis 29(4):1565-1578, 2023. e-Pub 2023. PMID: 35322907.
27. Landy R, Haber G, Graubard BI, Campos NG, Sy S, Kim JJ, Burger EA, Cheung LC, Katki HA, Gillison ML, Chaturvedi AK. Upper age-limits for US male HPV-vaccination for oropharyngeal cancer prevention: A microsimulation-based modeling study. J Natl Cancer Inst 115(4):429-436, 2023. e-Pub 2023. PMID: 36655795.
28. Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J Clin Oncol 41(12):JCO2200332, 2023. e-Pub 2023. PMID: 36473143.
29. Akagi K, Symer DE, Mahmoud M, Jiang B, Goodwin S, Wangsa D, Li Z, Xiao W, Dunn JD, Ried T, Coombes KR, Sedlazeck FJ, Gillison ML. Intratumoral heterogeneity and clonal evolution induced by HPV integration. Cancer Discov 13(4):910-927, 2023. e-Pub 2023. PMID: 36715691.
30. Subramaniam RM, DeMora L, Yao M, Yom SS, Gillison M, Caudell JJ, Waldron J, Xia P, Chung CH, Truong MT, Echevarria M, Chan JW, Geiger JL, Mell L, Seaward S, Thorstad WL, Beitler JJ, Sultanem K, Blakaj D, Le QT. 18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus-Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002. J Nucl Med 64(3):362-367, 2023. e-Pub 2023. PMID: 36215572.
31. Psyrri A, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, Weiss J, Machiels JP, Baxi S, Vasilyev A, Karpenko A, Dvorkin M, Hsieh CY, Thungappa SC, Segura PP, Vynnychenko I, Haddad R, Kasper S, Mauz PS, Baker V, He P, Evans B, Wildsmith S, Olsson RF, Yovine A, Kurland JF, Morsli N, Seiwert TY, Investigators K. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann Oncol 34(3):262-274, 2023. e-Pub 2023. PMID: 36535565.
32. Gillison ML, Ferris RL, Harris J, Colevas AD, Mell LK, Kong C, Jordan RC, Moore KL, Truong MT, Kirsch C, Chakravarti A, Blakaj DM, Clump DA, Ohr JP, Deeken JF, Gensheimer MF, Saba NF, Dorth JA, Rosenthal DI, Leidner RS, Kimple RJ, Machtay M, Curran WJ, Torres-Saavedra P, Le QT. Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Radiation Therapy Oncology Group Foundation 3504. Int J Radiat Oncol Biol Phys 115(4):847-860, 2023. e-Pub 2023. PMID: 36228746.
33. Wei F, Goodman MT, Xia N, Zhang J, Giuliano AR, D'Souza G, Hessol NA, Schim van der Loeff MF, Dai J, Neukam K, de Pokomandy A, Poynten IM, Geskus RB, Burgos J, Etienney I, Moscicki AB, Donà MG, Gillison ML, Nyitray AG, Nowak RG, Yunihastuti E, Zou H, Hidalgo-Tenorio C, Phanuphak N, Molina JM, Schofield AM, Kerr S, Fan S, Lu Y, Ong JJ, Chikandiwa AT, Teeraananchai S, Squillace N, Wiley DJ, Palefsky JM, Georges D, Alberts CJ, Clifford GM. Incidence and clearance of anal human papillomavirus infection in 16 164 individuals, according to HIV status, gender, and male sexuality: an international pooled analysis of 34 longitudinal studies. Clin Infect Dis 76(3):e692-e701, 2023. e-Pub 2023. PMID: 35869839.
34. Vogtmann E, Chaturvedi AK, Blaser MJ, Bokulich NA, Caporaso JG, Gillison ML, Hua X, Hullings AG, Knight R, Purandare V, Shi J, Wan Y, Freedman ND, Abnet CC. Representative oral microbiome data for the US population: the National Health and Nutrition Examination Survey. Lancet Microbe 4(2):e60-e61, 2023. e-Pub 2023. PMID: 36455567.
35. Coleman, N, Marcelo, KL, Hopkins, JF, Khan, NI, Du, R, Hong, L, Park, E, Balsara, B, Leoni, M, Pickering, CR, Myers, JN, Heymach, JV, Albacker, LA, Hong, DS, Gillison, M, Le, X. HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma. JCO Precision Oncology 7, 2023. e-Pub 2023. PMID: 36603172.
36. Nathan CO, Hayes DN, Karrison T, Harismendy O, Flores JM, Moore-Medlin T, Vokes EE, Gutkind JS, Neupane P, Mills G, Sargi Z, Seiwert T, Grilley-Olson J, Day T, Gillison M, Wade JL, Feldman L, Jha G, Kozloff M, O'Leary M, Worden FP, Cohen EEW. A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res 28(23):5040-5048, 2022. e-Pub 2022. PMID: 36194164.
37. Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, Blumenschein G, Lu C, Johnson FM, Bell D, Lewis J, Zhang J, Feng L, Wilson K, Marcelo-Lewis K, Wang J, Ginsberg L, Gillison M, Lee JJ, Meric-Bernstam F, Mills GB, William WN, Myers JN, Pickering CR. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res 28(13):2796-2806, 2022. e-Pub 2022. PMID: 35443062.
38. Gillison, M. Treatment De-Intensification for Patients With HPV-Positive Head and Neck Cancers. JNCCN Journal of the National Comprehensive Cancer Network 20(5.5):596-599, 2022. e-Pub 2022.
39. Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, Tang A, Mark J, Zender C, Gillenwater AM, Bell D, Kurtzweil N, Mathews M, Allen CL, Mierzwa ML, Casper K, Jandarov R, Medvedovic M, Lee JJ, Harun N, Takiar V, Gillison M. Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 28(7):1345-1352, 2022. e-Pub 2022. PMID: 35338369.
40. Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Wei L, Ferris RL. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist 27(2):e194-e198, 2022. e-Pub 2022. PMID: 35641218.
41. Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D, Birkeland AC, Brizel DM, Busse PM, Cmelak AJ, Colevas AD, Eisele DW, Galloway T, Geiger JL, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Mell LK, Mittal BB, Pinto HA, Rocco JW, Rodriguez CP, Savvides PS, Schwartz D, Shah JP, Sher D, St John M, Weber RS, Weinstein G, Worden F, Yang Bruce J, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. J Natl Compr Canc Netw 20(3):224-234, 2022. e-Pub 2022. PMID: 35276673.
42. Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol 40(2):JCO2101752, 2022. e-Pub 2022. PMID: 34699271.
43. Symer DE, Akagi K, Geiger HM, Song Y, Li G, Emde AK, Xiao W, Jiang B, Corvelo A, Toussaint NC, Li J, Agrawal A, Ozer E, El-Naggar AK, Du Z, Shewale JB, Stache-Crain B, Zucker M, Robine N, Coombes KR, Gillison ML. Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers. Genome Res 32(1):55-70, 2022. e-Pub 2022. PMID: 34903527.
44. Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck 44(1):158-167, 2022. e-Pub 2022. PMID: 34729846.
45. Giraldi L, Collatuzzo G, Hashim D, Franceschi S, Herrero R, Chen C, Schwartz SM, Smith E, Kelsey K, McClean M, Gillison M, Boccia S, Hashibe M, Amy Lee YC, Boffetta P. Infection with Human Papilloma Virus (HPV) and risk of subsites within the oral cancer. Cancer Epidemiol 75:102020, 2021. e-Pub 2021. PMID: 34509873.
46. Shewale JB, Pickard RKL, Xiao W, Jiang B, Gillison ML. Independent association of marijuana use and poor oral hygiene with HPV-negative but not HPV-positive head and neck squamous cell carcinomas. Cancer 127(12):2099-2110, 2021. e-Pub 2021. PMID: 33620741.
47. Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross ND. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck 43(5):1592-1603, 2021. e-Pub 2021. PMID: 33522021.
48. Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison MLL, Xia P, Truong MT, Kong C, Jordan R, Subramaniam RM, Yao M, Chung CH, Geiger JL, Chan JW, O'Sullivan B, Blakaj DM, Mell LK, Thorstad WL, Jones CU, Banerjee RN, Lominska C, Le QT. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). J Clin Oncol 39(9):JCO2003128, 2021. e-Pub 2021. PMID: 33507809.
49. Lam H, McNeil LK, Starobinets H, DeVault VL, Cohen RB, Twardowski P, Johnson ML, Gillison ML, Stein MN, Vaishampayan UN, DeCillis AP, Foti JJ, Vemulapalli V, Tjon E, Ferber K, DeOliveira DB, Broom W, Agnihotri P, Jaffee EM, Wong KK, Drake CG, Carroll PM, Davis TA, Flechtner JB. An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth. Cancer Discov 11(3):696-713, 2021. e-Pub 2021. PMID: 33504579.
50. Gunn GB, Garden AS, Ye R, Ausat N, Dahlstrom KR, Morrison WH, Fuller CD, Phan J, Reddy JP, Shah SJ, Mayo LL, Chun SG, Chronowski GM, Moreno AC, Myers JN, Hanna EY, Esmaeli B, Gillison ML, Ferrarotto R, Hutcheson KA, Chambers MS, Ginsberg LE, El-Naggar AK, Rosenthal DI, Zhu XR, Frank SJ. Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. Int J Part Ther 8(1):108-118, 2021. e-Pub 2021. PMID: 34285940.
51. Bahig H, Gunn BG, Garden AS, Ye R, Hutcheson K, Rosenthal DI, Phan J, Fuller CD, Morrison WH, Reddy JP, Ng SP, Gross ND, Sturgis EM, Ferrarotto R, Gillison M, Frank SJ. Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. Int J Part Ther 8(1):213-222, 2021. e-Pub 2021. PMID: 34285948.
52. Wang L, Fossati P, Paganetti H, Ma L, Gillison M, Myers JN, Hug E, Frank SJ. The Biological Basis for Enhanced Effects of Proton Radiation Therapy Relative to Photon Radiation Therapy for Head and Neck Squamous Cell Carcinoma. Int J Part Ther 8(1):3-13, 2021. e-Pub 2021. PMID: 34285931.
53. Sherry AD, Pasalic D, Gunn GB, Fuller CD, Phan J, Rosenthal DI, Morrison WH, Sturgis EM, Gross ND, Gillison ML, Ferrarotto R, El-Naggar AK, Garden AS, Frank SJ. Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. Int J Part Ther 8(1):234-247, 2021. e-Pub 2021. PMID: 34285950.
54. Di Credico G, Polesel J, Dal Maso L, Pauli F, Torelli N, Luce D, Radoï L, Matsuo K, Serraino D, Brennan P, Holcatova I, Ahrens W, Lagiou P, Canova C, Richiardi L, Healy CM, Kjaerheim K, Conway DI, Macfarlane GJ, Thomson P, Agudo A, Znaor A, Franceschi S, Herrero R, Toporcov TN, Moyses RA, Muscat J, Negri E, Vilensky M, Fernandez L, Curado MP, Menezes A, Daudt AW, Koifman R, Wunsch-Filho V, Olshan AF, Zevallos JP, Sturgis EM, Li G, Levi F, Zhang ZF, Morgenstern H, Smith E, Lazarus P, La Vecchia C, Garavello W, Chen C, Schwartz SM, Zheng T, Vaughan TL, Kelsey K, McClean M, Benhamou S, Hayes RB, Purdue MP, Gillison M, Schantz S, Yu GP, Chuang SC, Boffetta P, Hashibe M, Yuan-Chin AL, Edefonti V. Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration. Br J Cancer 123(9):1456-1463, 2020. e-Pub 2020. PMID: 32830199.
55. Yen CJ, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). Head Neck 42(10):2852-2862, 2020. e-Pub 2020. PMID: 32583557.
56. D'Souza G, Clemens G, Strickler HD, Wiley DJ, Troy T, Struijk L, Gillison M, Fakhry C. Long-term Persistence of Oral HPV Over 7 Years of Follow-up. JNCI Cancer Spectr 4(5):pkaa047, 2020. e-Pub 2020. PMID: 33225205.
57. Kreimer AR, Chaturvedi AK, Alemany L, Anantharaman D, Bray F, Carrington M, Doorbar J, D'Souza G, Fakhry C, Ferris RL, Gillison M, Neil Hayes D, Hildesheim A, Huang SH, Kowalski LP, Lang Kuhs KA, Lewis J, Lowy DR, Mehanna H, Ness A, Pawlita M, Pinheiro M, Schiller J, Shiels MS, Tota J, Mirabello L, Warnakulasuriya S, Waterboer T, Westra W, Chanock S, Brennan P. Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. Oral Oncol 108:104736, 2020. e-Pub 2020. PMID: 32502860.
58. Mehanna H, Rischin D, Wong SJ, Gregoire V, Ferris R, Waldron J, Le QT, Forster M, Gillison M, Laskar S, Tahara M, Psyrri A, Vermorken J, Porceddu S. De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. J Clin Oncol 38(22):JCO2000056, 2020. e-Pub 2020. PMID: 32496903.
59. Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, Phan J, Elamin YY, Torman DK, Warneke CL, Hessel AC, Garden AS, Myers JN, Johnson FM, Lee JJ, Sikora AG, Gillison ML, Glisson BS, Gross ND. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial. Clin Cancer Res 26(13):3211-3219, 2020. e-Pub 2020. PMID: 32269052.
60. Mehanna H, Gillison M, Lee AWM, von Zeidler SV, Porceddu S, Group (HNCIG) HANI. Adapting Head and Neck Cancer Management in the Time of COVID-19. Int J Radiat Oncol Biol Phys 107(4):628-630, 2020. e-Pub 2020. PMID: 32589989.
61. Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, Bruce JY, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Galloway T, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco JW, Rodriguez CP, Shah JP, Weber RS, Weinstein G, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(7):873-898, 2020. e-Pub 2020. PMID: 32634781.
62. MD Anderson Head and Neck Surgery Treatment Guidelines Consortium MD, members C, Maniakas A, Jozaghi Y, Zafereo ME, Sturgis EM, Su SY, Gillenwater AM, Gidley PW, Lewis CM, Diaz E, Goepfert RP, Kupferman ME, Gross ND, Hessel AC, Pytynia KB, Nader ME, Wang JR, Lango MN, Kiong KL, Guo T, Zhao X, CMKL Y, Appelbaum E, Alpard J, Garcia JA, Terry S, Flynn JE, Bauer S, Fournier D, Burgess CG, Wideman C, Johnston M, You C, De Luna R, Joseph L, Diersing J, Prescott K, Heiberger K, Mugartegui L, Rodriguez J, Zendehdel S, Sellers J, Friddell RA, Thomas A, Khanjae SJ, Schwarzlose KB, Chambers MS, Hofstede TM, Cardoso RC, Wesson RA, Won A, Otun AO, Gombos DS, Al-Zubidi N, Hutcheson KA, Gunn GB, Rosenthal DI, Gillison ML, Ferrarotto R, Weber RS, Hanna EY, Myers JN, Lai SY. Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. Head Neck 42(6):1194-1201, 2020. e-Pub 2020. PMID: 32342541.
63. Lee YA, Al-Temimi M, Ying J, Muscat J, Olshan AF, Zevallos JP, Winn DM, Li G, Sturgis EM, Morgenstern H, Zhang ZF, Smith E, Kelsey K, McClean M, Vaughan TL, Lazarus P, Chen C, Schwartz SM, Gillison M, Schantz S, Yu GP, D'Souza G, Gross N, Monroe M, Kim J, Boffetta P, Hashibe M. Head and Neck Cancer Risk Prediction Models for the US Population from the INHANCE Consortium. Am J Epidemiol 189(4):330-342, 2020. e-Pub 2020. PMID: 31781743.
64. Broutian TR, Jiang B, Li J, Akagi K, Gui S, Zhou Z, Xiao W, Symer DE, Gillison ML. Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma. Cancer Lett 476:23-33, 2020. e-Pub 2020. PMID: 31958486.
65. Chaturvedi AK, Graubard BI, Gillison ML. Herd Protection Against Oral HPV Infection-Reply. JAMA 323(5):478, 2020. e-Pub 2020. PMID: 32016305.
66. Tota JE, Gillison ML, Katki HA, Kahle L, Pickard RK, Xiao W, Jiang B, Graubard BI, Chaturvedi AK. Development and validation of an individualized risk prediction model for oropharynx cancer in the US population. Cancer 125(24):4407-4416, 2019. e-Pub 2019. PMID: 31454434.
67. Saba NF, Blumenschein G, Guigay J, Licitra L, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Brossart P. Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. Oral Oncol 96:7-14, 2019. e-Pub 2019. PMID: 31422216.
68. Coghill AE, Bellizzi AM, Lynch CF, Shiels MS, Selk FR, Gillison M, Hernandez BY, Chan OTM, Engels EA. Pathology characterization and detection of human papillomavirus type 16 in rectal squamous cell carcinomas. Clin Gastroenterol Hepatol 17(10):2129-2131, 2019. e-Pub 2019. PMID: 30448596.
69. Haddad R, Concha-Benavente F, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer 125(18):3208-3218, 2019. e-Pub 2019. PMID: 31246283.
70. Chaturvedi AK, Graubard BI, Broutian T, Xiao W, Pickard RKL, Kahle L, Gillison ML. Prevalence of Oral HPV Infection in Unvaccinated Men and Women in the United States, 2009-2016. JAMA 322(10):977-979, 2019. e-Pub 2019. PMID: 31503300.
71. Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML. Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res 25(17):5221-5230, 2019. e-Pub 2019. PMID: 31239321.
72. Fakhry C, Blackford AL, Neuner G, Xiao W, Jiang B, Agrawal A, Gillison ML. Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. JAMA Oncol 5(7):985-992, 2019. e-Pub 2019. PMID: 31046104.
73. Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 7(1):184, 2019. e-Pub 2019. PMID: 31307547.
74. Di Credico G, Edefonti V, Polesel J, Pauli F, Torelli N, Serraino D, Negri E, Luce D, Stucker I, Matsuo K, Brennan P, Vilensky M, Fernandez L, Curado MP, Menezes A, Daudt AW, Koifman R, Wunsch-Filho V, Holcatova I, Ahrens W, Lagiou P, Simonato L, Richiardi L, Healy C, Kjaerheim K, Conway DI, Macfarlane TV, Thomson P, Agudo A, Znaor A, Boaventura Rios LF, Toporcov TN, Franceschi S, Herrero R, Muscat J, Olshan AF, Zevallos JP, La Vecchia C, Winn DM, Sturgis EM, Li G, Fabianova E, Lissowska J, Mates D, Rudnai P, Shangina O, Swiatkowska B, Moysich K, Zhang ZF, Morgenstern H, Levi F, Smith E, Lazarus P, Bosetti C, Garavello W, Kelsey K, McClean M, Ramroth H, Chen C, Schwartz SM, Vaughan TL, Zheng T, Menvielle G, Boccia S, Cadoni G, Hayes RB, Purdue M, Gillison M, Schantz S, Yu GP, Brenner H, D'Souza G, Gross ND, Chuang SC, Boffetta P, Hashibe M, Lee YA, Dal Maso L. Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach. Oral Oncol 94:47-57, 2019. e-Pub 2019. PMID: 31178212.
75. Fakhry C, Zhang Q, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM, Barrett WL, Thorstad WL, Yom SS, Wong SJ, Ridge JA, Rao SSD, Spencer S, Fortin A, Raben D, Harris J, Le QT. Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials. Cancer 125(12):2027-2038, 2019. e-Pub 2019. PMID: 30913305.
76. Tota JE, Best AF, Zumsteg ZS, Gillison ML, Rosenberg PS, Chaturvedi AK. Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals. J Clin Oncol 37(18):JCO1900370, 2019. e-Pub 2019. PMID: 31026209.
77. Hernandez BY, Lynch CF, Chan OTM, Goodman MT, Unger ER, Steinau M, Thompson TD, Gillison M, Lyu C, Saraiya M, HPV Typing of Cancer Workgroup HPV. Human papillomavirus DNA detection, p16INK4a, and oral cavity cancer in a U.S. population. Oral Oncol 91:92-96, 2019. e-Pub 2019. PMID: 30926069.
78. Rindal DB, Gilbert GH, Carcelén C, Funkhouser E, Durand E, Uppgaard DA, Fellows J, Ikeda J, Kerr AR, Brar B, Gordan VV, Agarwal S, Barnett P, Pickard RK, Gillison M, Research Network NDP. Feasibility and acceptance of oral human papillomavirus detection in the dental office: Results from The National Dental Practice-Based Research Network. J Am Dent Assoc 150(2):130-139.e4, 2019. e-Pub 2019. PMID: 30691571.
79. Gillison ML, Akagi K, Xiao W, Jiang B, Pickard RKL, Li J, Swanson BJ, Agrawal AD, Zucker M, Stache-Crain B, Emde AK, Geiger HM, Robine N, Coombes KR, Symer DE. Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. Genome Res 29(1):1-17, 2019. e-Pub 2019. PMID: 30563911.
80. Gleber-Netto FO, Rao X, Guo T, Xi Y, Gao M, Shen L, Erikson K, Kalu NN, Ren S, Xu G, Fisch KM, Akagi K, Seiwert T, Gillison M, Frederick MJ, Johnson FM, Wang J, Myers JN, Califano J, Skinner HD, Pickering CR. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight 4(1). e-Pub 2019. PMID: 30626753.
81. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393(10166):40-50, 2019. e-Pub 2019. PMID: 30449625.
82. Fakhry C, Nguyen-Tân PF, Lambert L, Rosenthal DI, Weber RS, Gillison ML, Trotti AM, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT. In Regard to Bossi et al. Int J Radiat Oncol Biol Phys 102(3):669-670, 2018. e-Pub 2018. PMID: 30238902.
83. Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist 23(9):1079-1082, 2018. e-Pub 2018. PMID: 29866947.
84. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81:45-51, 2018. e-Pub 2018. PMID: 29884413.
85. Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw 16(5):479-490, 2018. e-Pub 2018. PMID: 29752322.
86. Voltzke KJ, Lee YA, Zhang ZF, Zevallos JP, Yu GP, Winn DM, Vaughan TL, Sturgis EM, Smith E, Schwartz SM, Schantz S, Muscat J, Morgenstern H, McClean M, Li G, Lazarus P, Kelsey K, Gillison M, Chen C, Boffetta P, Hashibe M, Olshan AF. Racial differences in the relationship between tobacco, alcohol, and the risk of head and neck cancer: pooled analysis of US studies in the INHANCE Consortium. Cancer Causes Control. e-Pub 2018. PMID: 29761303.
87. Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran R, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 36(10):JCO2017770446, 2018. e-Pub 2018. PMID: 29380678.
88. Warburton A, Redmond CJ, Dooley KE, Fu H, Gillison ML, Akagi K, Symer DE, Aladjem MI, McBride AA. HPV integration hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that drives high viral oncogene expression. PLoS Genet 14(1):e1007179, 2018. e-Pub 2018. PMID: 29364907.
89. Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong ZY, Xiao W, Kahle L, Gillison ML. Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J Clin Oncol 36(3):262-267, 2018. e-Pub 2018. PMID: 29182497.
90. Fakhry C, Zhang Q, Nguyen-Tân PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT, Gillison ML. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. J Clin Oncol 35(36):4057-4065, 2017. e-Pub 2017. PMID: 28777690.
91. Jensen GL, Blanchard P, Gunn GB, Garden AS, David Fuller C, Sturgis EM, Gillison ML, Phan J, Morrison WH, Rosenthal DI, Frank SJ. Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. Clin Transl Radiat Oncol 7:28-35, 2017. e-Pub 2017. PMID: 29594226.
92. Börnigen D, Ren B, Pickard R, Li J, Ozer E, Hartmann EM, Xiao W, Tickle T, Rider J, Gevers D, Franzosa EA, Davey ME, Gillison ML, Huttenhower C. Alterations in oral bacterial communities are associated with risk factors for oral and oropharyngeal cancer. Sci Rep 7(1):17686, 2017. e-Pub 2017. PMID: 29247187.
93. Taberna M, Mena M, Pavón MA, Alemany L, Gillison ML, Mesía R. Human papillomavirus related oropharyngeal cancer. Ann Oncol 28(10):2386-2398, 2017. e-Pub 2017. PMID: 28633362.
94. Kiyota N, Hasegawa Y, Takahashi S, Yokota T, Yen CJ, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Sum Kenneth Li W, Ferris RL, Gillison M, Namba Y, Monga M, Lynch M, Tahara M. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncol 73:138-146, 2017. e-Pub 2017. PMID: 28939066.
95. Wyss AB, Hashibe M, Lee YA, Chuang SC, Muscat J, Chen C, Schwartz SM, Smith E, Zhang ZF, Morgenstern H, Wei Q, Li G, Kelsey KT, Winn DM, Gillison ML, Zevallos JP, Boffetta P, Olshan AF. THE AUTHORS REPLY. Am J Epidemiol 186(5):625-626, 2017. e-Pub 2017. PMID: 28911015.
96. Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 18(8):1104-1115, 2017. e-Pub 2017. PMID: 28651929.
97. Miller ED, Blakaj DM, Swanson BJ, Xiao W, Gillison ML, Wei L, Bhatt AD, Diavolitsis VM, Wobb JL, Kang SY, Carrau RL, Grecula JC. Sinonasal adenoid cystic carcinoma: Treatment outcomes and association with human papillomavirus. Head Neck 39(7):1405-1411, 2017. e-Pub 2017. PMID: 28370900.
98. Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw 15(6):761-770, 2017. e-Pub 2017. PMID: 28596256.
99. Taberna M, Inglehart RC, Pickard RK, Fakhry C, Agrawal A, Katz ML, Gillison ML. Significant changes in sexual behavior after a diagnosis of human papillomavirus-positive and human papillomavirus-negative oral cancer. Cancer 123(7):1156-1165, 2017. e-Pub 2017. PMID: 28195638.
100. Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer 123(7):1259-1271, 2017. e-Pub 2017. PMID: 27906454.
101. Yuan H, Krawczyk E, Blancato J, Albanese C, Zhou D, Wang N, Paul S, Alkhilaiwi F, Palechor-Ceron N, Dakic A, Fang S, Choudhary S, Hou TW, Zheng YL, Haddad BR, Usuda Y, Hartmann D, Symer D, Gillison M, Agarwal S, Wangsa D, Ried T, Liu X, Schlegel R. HPV positive neuroendocrine cervical cancer cells are dependent on Myc but not E6/E7 viral oncogenes. Sci Rep 7:45617, 2017. e-Pub 2017. PMID: 28378747.
102. Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol 35(5):490-497, 2017. e-Pub 2017. PMID: 28029303.
103. Lam JO, Sugar EA, Cranston RD, Weber KM, Burk RD, Wiley DJ, Reddy S, Margolick JB, Strickler HD, Wentz A, Jacobson L, Coles CL, Bream JH, Rositch AF, Guo Y, Xiao W, Gillison ML, D'Souza G. The association of medication use with clearance or persistence of oral HPV infection. Cancer Causes Control 27(12):1491-1498, 2016. e-Pub 2016. PMID: 27804058.
104. Inglehart RC, Taberna M, Pickard RK, Hoff M, Fakhry C, Ozer E, Katz M, Gillison ML. HPV knowledge gaps and information seeking by oral cancer patients. Oral Oncol 63:23-29, 2016. e-Pub 2016. PMID: 27938996.
105. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 375(19):1856-1867, 2016. e-Pub 2016. PMID: 27718784.
106. Kahn JA, Rudy BJ, Xu J, Kapogiannis B, Secord E, Gillison M. Prevalence and risk factors for oral DNA tumor viruses in HIV-infected youth. J Med Virol 88(11):1944-52, 2016. e-Pub 2016. PMID: 27096166.
107. Taberna M, Resteghini C, Swanson B, Pickard RK, Jiang B, Xiao W, Mena M, Kreinbrink P, Chio E, Gillison ML. Low etiologic fraction for human papillomavirus in larynx squamous cell carcinoma. Oral Oncol 61:55-61, 2016. e-Pub 2016. PMID: 27688105.
108. Wyss AB, Hashibe M, Lee YA, Chuang SC, Muscat J, Chen C, Schwartz SM, Smith E, Zhang ZF, Morgenstern H, Wei Q, Li G, Kelsey KT, McClean M, Winn DM, Schantz S, Yu GP, Gillison ML, Zevallos JP, Boffetta P, Olshan AF. Smokeless Tobacco Use and the Risk of Head and Neck Cancer: Pooled Analysis of US Studies in the INHANCE Consortium. Am J Epidemiol 184(10):703-16. e-Pub 2016. PMID: 27744388.
109. Chaturvedi AK, D'Souza G, Gillison ML, Katki HA. Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. Oral Oncol 60:61-7, 2016. e-Pub 2016. PMID: 27531874.
110. Zhang Y, Waterboer T, Pawlita M, Sugar E, Minkoff H, Cranston RD, Wiley D, Burk R, Reddy S, Margolick J, Strickler H, Weber K, Gillison M, D'Souza G. Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection. Cancer Epidemiol 43:30-34, 2016. e-Pub 2016. PMID: 27344614.
111. Boffetta P, Hayes RB, Sartori S, Lee YC, Muscat J, Olshan A, Winn DM, Castellsagué X, Zhang ZF, Morgenstern H, Chen C, Schwartz SM, Vaughan TL, Wunsch-Filho V, Purdue M, Koifman S, Curado MP, Vilensky M, Gillison M, Fernandez L, Menezes A, Daudt AW, Schantz S, Yu G, D'Souza G, Haddad RI, La Vecchia C, Hashibe M. Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev 25(4):344-8, 2016. e-Pub 2016. PMID: 26275006.
112. Lam JO, Bream JH, Sugar EA, Coles CL, Weber KM, Burk RD, Wiley DJ, Cranston RD, Reddy S, Margolick JB, Strickler HD, Wentz A, Jacobson L, Guo Y, Xiao W, Gillison ML, D'Souza G. Association of serum cytokines with oral HPV clearance. Cytokine 83:85-91, 2016. e-Pub 2016. PMID: 27064455.
113. D'Souza G, Wentz A, Kluz N, Zhang Y, Sugar E, Youngfellow RM, Guo Y, Xiao W, Gillison ML. Sex Differences in Risk Factors and Natural History of Oral Human Papillomavirus Infection. J Infect Dis 213(12):1893-6, 2016. e-Pub 2016. PMID: 26908748.
114. Romick-Rosendale LE, Hoskins EE, Privette Vinnedge LM, Foglesong GD, Brusadelli MG, Potter SS, Komurov K, Brugmann SA, Lambert PF, Kimple RJ, Virts EL, Hanenberg H, Gillison ML, Wells SI. Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling. Clin Cancer Res 22(8):2062-73, 2016. e-Pub 2016. PMID: 26603260.
115. Castro FA, Koshiol J, Quint W, Wheeler CM, Gillison ML, Vaughan LM, Kleter B, van Doorn LJ, Chaturvedi AK, Hildesheim A, Schiffman M, Wang SS, Zuna RE, Walker JL, Dunn ST, Wentzensen N. Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. BMC Infect Dis 15:544, 2015. e-Pub 2015. PMID: 26607224.
116. Fakhry C, Andersen KK, Eisele DW, Gillison ML. Oropharyngeal cancer survivorship in Denmark, 1977-2012. Oral Oncol 51(11):982-4, 2015. e-Pub 2015. PMID: 26319353.
117. Beachler DC, Guo Y, Xiao W, Burk RD, Minkoff H, Strickler HD, Cranston RD, Wiley DJ, Jacobson LP, Weber KM, Margolick JB, Sugar EA, Reddy S, Gillison ML, D'Souza G. High Oral Human Papillomavirus Type 16 Load Predicts Long-term Persistence in Individuals With or at Risk for HIV Infection. J Infect Dis 212(10):1588-91, 2015. e-Pub 2015. PMID: 25954049.
118. Rettig EM, Wentz A, Posner MR, Gross ND, Haddad RI, Gillison ML, Fakhry C, Quon H, Sikora AG, Stott WJ, Lorch JH, Gourin CG, Guo Y, Xiao W, Miles BA, Richmon JD, Andersen PE, Misiukiewicz KJ, Chung CH, Gerber JE, Rajan SD, D'Souza G. Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. JAMA Oncol 1(7):907-15, 2015. e-Pub 2015. PMID: 26226294.
119. Anderson KS, Gerber JE, D'Souza G, Pai SI, Cheng JN, Alam R, Kesiraju S, Chowell D, Gross ND, Haddad R, Gillison ML, Posner M. Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncol 51(8):751-8, 2015. e-Pub 2015. PMID: 26094591.
120. Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M. Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw 13(7):847-55; quiz 856, 2015. e-Pub 2015. PMID: 26150579.
121. Chaturvedi AK, Graubard BI, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, Gillison ML. NHANES 2009-2012 Findings: Association of Sexual Behaviors with Higher Prevalence of Oral Oncogenic Human Papillomavirus Infections in U.S. Men. Cancer Res 75(12):2468-77, 2015. e-Pub 2015. PMID: 25873485.
122. Kahn JA, Rudy BJ, Xu J, Secord EA, Kapogiannis BG, Thornton S, Gillison ML. Behavioral, immunologic, and virologic correlates of oral human papillomavirus infection in HIV-infected youth. Sex Transm Dis 42(5):246-52, 2015. e-Pub 2015. PMID: 25868136.
123. Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar AK, Garden AS, Soulieres D, Trotti A, Avizonis VN, Ridge JA, Harris J, Le QT, Gillison M. Reply to B. O'Sullivan et Al. J Clin Oncol 33(15):1708-9, 2015. e-Pub 2015. PMID: 25823732.
124. Conway DI, Brenner DR, McMahon AD, Macpherson LM, Agudo A, Ahrens W, Bosetti C, Brenner H, Castellsague X, Chen C, Curado MP, Curioni OA, Dal Maso L, Daudt AW, de Gois Filho JF, D'Souza G, Edefonti V, Fabianova E, Fernandez L, Franceschi S, Gillison M, Hayes RB, Healy CM, Herrero R, Holcatova I, Jayaprakash V, Kelsey K, Kjaerheim K, Koifman S, La Vecchia C, Lagiou P, Lazarus P, Levi F, Lissowska J, Luce D, Macfarlane TV, Mates D, Matos E, McClean M, Menezes AM, Menvielle G, Merletti F, Morgenstern H, Moysich K, Müller H, Muscat J, Olshan AF, Purdue MP, Ramroth H, Richiardi L, Rudnai P, Schantz S, Schwartz SM, Shangina O, Simonato L, Smith E, Stucker I, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Thomson P, Vaughan TL, Wei Q, Winn DM, Wunsch-Filho V, Yu GP, Zhang ZF, Zheng T, Znaor A, Boffetta P, Chuang SC, Ghodrat M, Amy Lee YC, Hashibe M, Brennan P. Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. Int J Cancer 136(5):1125-39, 2015. e-Pub 2015. PMID: 24996155.
125. Adams AK, Hallenbeck GE, Casper KA, Patil YJ, Wilson KM, Kimple RJ, Lambert PF, Witte DP, Xiao W, Gillison ML, Wikenheiser-Brokamp KA, Wise-Draper TM, Wells SI. DEK promotes HPV-positive and -negative head and neck cancer cell proliferation. Oncogene 34(7):868-77, 2015. e-Pub 2015. PMID: 24608431.
126. Beachler DC, Viscidi R, Sugar EA, Minkoff H, Strickler HD, Cranston RD, Wiley DJ, Jacobson LP, Weber KM, Margolick JB, Reddy S, Gillison ML, D'Souza G. A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection. Sex Transm Dis 42(2):93-7, 2015. e-Pub 2015. PMID: 25585068.
127. Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, Le QT, Gillison ML. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 33(2):156-64, 2015. e-Pub 2015. PMID: 25488965.
128. Robbins HA, Fennell CE, Gillison M, Xiao W, Guo Y, Wentz A, Kirk GD, Mehta SH, D'Souza G. Prevalence of and Risk Factors for Oral Human Papillomavirus Infection among HIV-Positive and HIV-Negative People Who Inject Drugs. PLoS One 10(11):e0143698, 2015. e-Pub 2015. PMID: 26600158.
129. Beachler DC, Sugar EA, Margolick JB, Weber KM, Strickler HD, Wiley DJ, Cranston RD, Burk RD, Minkoff H, Reddy S, Xiao W, Guo Y, Gillison ML, D'Souza G. Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol 181(1):40-53, 2015. e-Pub 2015. PMID: 25480823.
130. Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 32(35):3930-8, 2014. e-Pub 2014. PMID: 25267748.
131. Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 32(34):3858-66, 2014. e-Pub 2014. PMID: 25366680.
132. Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M, Cancer Network NC. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 12(10):1454-87, 2014. e-Pub 2014. PMID: 25313184.
133. Fakhry C, Gillison ML, D'Souza G. Tobacco use and oral HPV-16 infection. JAMA 312(14):1465-7, 2014. e-Pub 2014. PMID: 25291584.
134. Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, Soulieres D, Trotti A, Avizonis V, Ridge JA, Harris J, Le QT, Gillison M. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 32(30):3365-73, 2014. e-Pub 2014. PMID: 24958820.
135. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32(27):2940-50, 2014. e-Pub 2014. PMID: 25154822.
136. D'Souza G, Kluz N, Wentz A, Youngfellow RM, Griffioen A, Stammer E, Guo Y, Xiao W, Gillison ML. Oral Human Papillomavirus (HPV) Infection among Unvaccinated High-Risk Young Adults. Cancers (Basel) 6(3):1691-704, 2014. e-Pub 2014. PMID: 25256827.
137. Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, Straube W, Zhang Q, Ang K. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol 32(23):2486-95, 2014. e-Pub 2014. PMID: 25002723.
138. D'Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, Gerber J, Gillison ML, Posner MR. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol 32(23):2408-15, 2014. e-Pub 2014. PMID: 24778397.
139. Chaturvedi AK, Graubard BI, Pickard RK, Xiao W, Gillison ML. High-risk oral human papillomavirus load in the US population, National Health and Nutrition Examination Survey 2009-2010. J Infect Dis 210(3):441-7, 2014. e-Pub 2014. PMID: 24625808.
140. Fakhry C, Agrawal N, Califano J, Messing B, Liu J, Saunders J, Ha P, Coquia S, Hamper U, Gillison M, Blanco R. The use of ultrasound in the search for the primary site of unknown primary head and neck squamous cell cancers. Oral Oncol 50(7):640-5, 2014. e-Pub 2014. PMID: 24819862.
141. Steinau M, Hariri S, Gillison ML, Broutian TR, Dunne EF, Tong ZY, Markowitz LE, Unger ER. Prevalence of cervical and oral human papillomavirus infections among US women. J Infect Dis 209(11):1739-43, 2014. e-Pub 2014. PMID: 24319284.
142. Gillison ML, Castellsagué X, Chaturvedi A, Goodman MT, Snijders P, Tommasino M, Arbyn M, Franceschi S. Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer 134(3):497-507, 2014. e-Pub 2014. PMID: 23568556.
143. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, Rocco JW, Teknos TN, Kumar B, Wangsa D, He D, Ried T, Symer DE, Gillison ML. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res 24(2):185-99, 2014. e-Pub 2014. PMID: 24201445.
144. Blanco RG, Califano J, Messing B, Richmon J, Liu J, Quon H, Neuner G, Saunders J, Ha PK, Sheth S, Gillison M, Fakhry C. Transcervical ultrasonography is feasible to visualize and evaluate base of tongue cancers. PLoS One 9(1):e87565, 2014. e-Pub 2014. PMID: 24498138.
145. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F, Gillison ML. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 31(36):4550-9, 2013. e-Pub 2013. PMID: 24248688.
146. Perez-Ordoñez B, Irish JC, Yu ES, Gillison ML. Human papillomavirus-16 associated adenocarcinoma NOS of base of tongue. Head Neck Pathol 7(3):268-73, 2013. e-Pub 2013. PMID: 23054956.
147. Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M, Cancer Network NC. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11(8):917-23, 2013. e-Pub 2013. PMID: 23946171.
148. Beachler DC, D'Souza G, Sugar EA, Xiao W, Gillison ML. Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis 208(2):330-9, 2013. e-Pub 2013. PMID: 23596319.
149. Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, Perez-Ordonez B, Jordan RC, Gillison ML. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol 49(1):1-8, 2013. e-Pub 2013. PMID: 22841678.
150. Hoskins EE, Morreale RJ, Werner SP, Higginbotham JM, Laimins LA, Lambert PF, Brown DR, Gillison ML, Nuovo GJ, Witte DP, Kim MO, Davies SM, Mehta PA, Butsch Kovacic M, Wikenheiser-Brokamp KA, Wells SI. The fanconi anemia pathway limits human papillomavirus replication. J Virol 86(15):8131-8, 2012. e-Pub 2012. PMID: 22623785.
151. Pickard RK, Xiao W, Broutian TR, He X, Gillison ML. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years. Sex Transm Dis 39(7):559-66, 2012. e-Pub 2012. PMID: 22706220.
152. Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M, Jiang B, Wakely P, Xiao W, Gillison ML. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36(7):945-54, 2012. e-Pub 2012. PMID: 22743284.
153. Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, Spencer S, Harris J, Chung CH, Ang KK. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30(17):2102-11, 2012. e-Pub 2012. PMID: 22565003.
154. Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf G, Worden F, Cancer Network NC. Mucosal melanoma of the head and neck. J Natl Compr Canc Netw 10(3):320-38, 2012. e-Pub 2012. PMID: 22393194.
155. Gilbert J, Rudek MA, Higgins MJ, Zhao M, Bienvenu S, Tsottles N, Chaudhry MA, Wahl R, Forastiere A, Gillison M. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. Clin Cancer Res 18(6):1735-42, 2012. e-Pub 2012. PMID: 22271880.
156. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, Graubard BI, Chaturvedi AK. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 307(7):693-703, 2012. e-Pub 2012. PMID: 22282321.
157. Fakhry C, Bajaj G, Aygun N, Westra W, Gillison M. Long-term survival of a patient with leptomeningeal involvement by nasopharyngeal carcinoma after treatment with high-dose intravenous methotrexate. Head Neck 34(2):296-300, 2012. e-Pub 2012. PMID: 20737501.
158. Beachler DC, Weber KM, Margolick JB, Strickler HD, Cranston RD, Burk RD, Wiley DJ, Minkoff H, Reddy S, Stammer EE, Gillison ML, D'Souza G. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev 21(1):122-33, 2012. e-Pub 2012. PMID: 22045700.
159. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29(32):4294-301, 2011. e-Pub 2011. PMID: 21969503.
160. Fakhry C, Rosenthal BT, Clark DP, Gillison ML. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res (Phila) 4(9):1378-84, 2011. e-Pub 2011. PMID: 21836021.
161. Broutian TR, He X, Gillison ML. Automated high throughput DNA isolation for detection of human papillomavirus in oral rinse samples. J Clin Virol 50(4):270-5, 2011. e-Pub 2011. PMID: 21273118.
162. Koshiol J, Rotunno M, Gillison ML, Van Doorn LJ, Chaturvedi AK, Tarantini L, Song H, Quint WG, Struijk L, Goldstein AM, Hildesheim A, Taylor PR, Wacholder S, Bertazzi PA, Landi MT, Caporaso NE. Assessment of human papillomavirus in lung tumor tissue. J Natl Cancer Inst 103(6):501-7, 2011. e-Pub 2011. PMID: 21293027.
163. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24-35, 2010. e-Pub 2010. PMID: 20530316.
164. Fakhry C, Sugar E, D'Souza G, Gillison M. Two-week versus six-month sampling interval in a short-term natural history study of oral HPV infection in an HIV-positive cohort. PLoS One 5(7):e11918, 2010. e-Pub 2010. PMID: 20689835.
165. Koshiol J, Wei WQ, Kreimer AR, Chen W, Gravitt P, Ren JS, Abnet CC, Wang JB, Kamangar F, Lin DM, von Knebel-Doeberitz M, Zhang Y, Viscidi R, Wang GQ, Gillison ML, Roth MJ, Dong ZW, Kim E, Taylor PR, Qiao YL, Dawsey SM. No role for human papillomavirus in esophageal squamous cell carcinoma in China. Int J Cancer 127(1):93-100, 2010. e-Pub 2010. PMID: 19918949.
166. D'Souza G, Zhang HH, D'Souza WD, Meyer RR, Gillison ML. Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. Oral Oncol 46(2):100-4, 2010. e-Pub 2010. PMID: 20036610.
167. Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, O'Sullivan B, Waldron J, Cummings B, Kim J, Ringash J, Dawson LA, Gullane P, Siu L, Gillison M, Liu FF. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 27(36):6213-21, 2009. e-Pub 2009. PMID: 19884544.
168. Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D'Souza G, Gravitt PE, Westra W, Psyrri A, Kast WM, Koutsky LA, Giuliano A, Krosnick S, Trotti A, Schuller DE, Forastiere A, Ullmann CD. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 31(11):1393-422, 2009. e-Pub 2009. PMID: 19787782.
169. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 199(9):1263-9, 2009. e-Pub 2009. PMID: 19320589.
170. Ryerson AB, Peters ES, Coughlin SS, Chen VW, Gillison ML, Reichman ME, Wu X, Chaturvedi AK, Kawaoka K. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 113(10 Suppl):2901-9, 2008. e-Pub 2008. PMID: 18980273.
171. Agrawal Y, Koch WM, Xiao W, Westra WH, Trivett AL, Symer DE, Gillison ML. Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin Cancer Res 14(21):7143-50, 2008. e-Pub 2008. PMID: 18981014.
172. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100(6):407-20, 2008. e-Pub 2008. PMID: 18334711.
173. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100(4):261-9, 2008. e-Pub 2008. PMID: 18270337.
174. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26(4):612-9, 2008. e-Pub 2008. PMID: 18235120.
175. Cmelak AJ, Li S, Goldwasser MA, Murphy B, Cannon M, Pinto H, Rosenthal DI, Gillison M, Forastiere AA. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 25(25):3971-7, 2007. e-Pub 2007. PMID: 17761982.
176. D'Souza G, Fakhry C, Sugar EA, Seaberg EC, Weber K, Minkoff HL, Anastos K, Palefsky JM, ML G. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 121(1):143-50, 2007. e-Pub 2007. PMID: 17354235.
177. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, ML G. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356(19):1944-56, 2007. e-Pub 2007. PMID: 17494927.
178. ML G, Chen R, Goshu E, Rushlow D, Chen N, Banister C, Creek KE, Gallie BL. Human retinoblastoma is not caused by known pRb-inactivating human DNA tumor viruses. Int J Cancer 120(7):1482-90, 2007. e-Pub 2007. PMID: 17205527.
179. Begum S, ML G, Nicol TL, Westra WH. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 13(4):1186-91, 2007. e-Pub 2007. PMID: 17317828.
180. Gillison ML. Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. J Clin Oncol 24(36):5623-5, 2006. e-Pub 2006. PMID: 17179099.
181. Nayer H, Murphy KM, Hawkins AL, Long PP, Gillison M, Borowitz M, Griffin CA. Clonal cytogenetic abnormalities and BCL2 rearrangement in interdigitating dendritic cell sarcoma. Leuk Lymphoma 47(12):2651-4, 2006. e-Pub 2006. PMID: 17169812.
182. Fakhry C, D'souza G, Sugar E, Weber K, Goshu E, Minkoff H, Wright R, Seaberg E, Gillison M. Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol 44(12):4479-85, 2006. e-Pub 2006. PMID: 17021055.
183. Brock MV, Hooker CM, Engels EA, Moore RD, Gillison ML, Alberg AJ, Keruly JC, Yang SC, Heitmiller RF, Baylin SB, Herman JG, Brahmer JR. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 43(1):47-55, 2006. e-Pub 2006. PMID: 16936558.
184. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 24(9):1383-8, 2006. e-Pub 2006. PMID: 16549832.
185. D'Souza G, Sugar E, Ruby W, Gravitt P, Gillison M. Analysis of the effect of DNA purification on detection of human papillomavirus in oral rinse samples by PCR. J Clin Microbiol 43(11):5526-35, 2005. e-Pub 2005. PMID: 16272481.
186. Begum S, Cao D, Gillison M Zahurak M, Westra WH. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 11(16):5694-9, 2005. e-Pub 2005. PMID: 16115905.
187. Kreimer AR, Alberg AJ, Viscidi R, Gillison ML. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis 31(4):247-56, 2004. e-Pub 2004. PMID: 15028941.
188. Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Garrett ES, Shah KV, Gillison ML. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 189(4):686-98, 2004. e-Pub 2004. PMID: 14767823.
189. Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9(17):6469-75, 2003. e-Pub 2003. PMID: 14695150.
190. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison ML, Pardoll D, Wu L, Wu TC. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 21(25-26):4036-42, 2003. e-Pub 2003. PMID: 12922140.
191. Ha PK, Pai SI, Westra WH, Gillison ML, Tong BC, Sidransky D, Califano JA. Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res 8(5):1203-9, 2002. e-Pub 2002. PMID: 12006539.
192. Capone RB, Pai SI, Koch WM, Gillison ML, Danish HN, Westra WH, Daniel R, Shah KV, Sidransky D. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res 6(11):4171-5, 2000. e-Pub 2000. PMID: 11106228.
193. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92(9):709-20, 2000. e-Pub 2000. PMID: 10793107.
194. Fearon ER, Finkel T, Gillison ML, Kennedy SP, Casella JF, Tomaselli GF, Morrow JS, Van Dang C. Karyoplasmic interaction selection strategy: a general strategy to detect protein-protein interactions in mammalian cells. Proc Natl Acad Sci U.S.A 89(17):7958-62, 1992. e-Pub 1992. PMID: 1387709.
195. Dang CV, Dolde C, Gillison ML, Kato GJ. Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins. Proc Natl Acad Sci U.S.A 89(2):599-602, 1992. e-Pub 1992. PMID: 1731330.
196. Richards RG, Brown OE, Gillison ML, Sedwick WD. Drug concentration-dependent DNA lesions are induced by the lipid-soluble antifolate, piritrexim (BW301U). Mol Pharmacol 30(6):651-8, 1986. e-Pub 1986. PMID: 3491287.

Review Articles

1. Bravi F, Lee YA, Hashibe M, Boffetta P, Conway DI, Ferraroni M, La Vecchia C, Edefonti V, investigators IC. Lessons learned from the INHANCE consortium: An overview of recent results on head and neck cancer. Oral Dis 27(1):73-93, 2021. e-Pub 2021. PMID: 32569410.
2. Le X, Ferrarotto R, Wise-Draper T, Gillison M. Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. J Natl Compr Canc Netw 18(7):899-906, 2020. e-Pub 2020. PMID: 32634775.
3. Shewale JB, Gillison ML. Dynamic factors affecting HPV-attributable fraction for head and neck cancers. Curr Opin Virol 39:33-40, 2019. e-Pub 2019. PMID: 31465959.
4. Gillison ML, Restighini C. Anticipation of the Impact of Human Papillomavirus on Clinical Decision Making for the Head and Neck Cancer Patient. Hematol Oncol Clin North Am 29(6):1045-60, 2015. e-Pub 2015. PMID: 26568547.
5. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol 33(29):3235-42, 2015. e-Pub 2015. PMID: 26351338.
6. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, Volume 30 AOTIM‘COHIARDV, 5 S, 2012. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 31 Suppl 8:I1-31, 2013. e-Pub 2013. PMID: 24229716.
7. Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, Castellsagué X. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 30 Suppl 5:F34-54, 2012. e-Pub 2012. PMID: 23199965.
8. Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL, Denny L, Bornstein J, Abramowitz L, Giuliano A, Tommasino M, Monsonego J. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 131(9):1969-82, 2012. e-Pub 2012. PMID: 22623137.
9. Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf GT, Worden F, Concer Network NC. Head and neck cancers. J Natl Compr Canc Netw 9(6):596-650, 2011. e-Pub 2011. PMID: 21636536.
10. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 15(22):6758-62, 2009. e-Pub 2009. PMID: 19861444.
11. Gillison ML. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 21(5):439-44, 2009. e-Pub 2009. PMID: 19587593.
12. Vidal L, Gillison ML. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am 22(6):1125-42, vii, 2008. e-Pub 2008. PMID: 19010263.
13. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113(10 Suppl):3036-46, 2008. e-Pub 2008. PMID: 18980286.
14. Gillison ML. Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health 43(4 Suppl):S52-60, 2008. e-Pub 2008. PMID: 18809146.
15. Gillison ML. Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck 29(8):779-92, 2007. e-Pub 2007. PMID: 17230556.
16. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 24 Suppl 3:S3/140-6, 2006. e-Pub 2006. PMID: 16950001.
17. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24(17):2606-11, 2006. e-Pub 2006. PMID: 16763272.
18. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31(6):744-54, 2004. e-Pub 2004. PMID: 15599852.
19. Devaraj K, Gillison ML, Wu TC. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med 14(5):345-62, 2003. e-Pub 2003. PMID: 14530303.
20. Gillison ML, Shah KV. Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 13(3):183-8, 2001. e-Pub 2001. PMID: 11307062.
21. Gillison ML, Forastiere AA. Larynx preservation in head and neck cancers. A discussion of the National Comprehensive Cancer Network Practice Guidelines. Hematol Oncol Clin North Am 13(4):699-718, vi, 1999. e-Pub 1999. PMID: 10494508.
22. Gillison ML, Koch WM, Shah KV. Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease?. Curr Opin Oncol 11(3):191-9, 1999. e-Pub 1999. PMID: 10328594.
23. Gillison ML, Ambinder RF. Human herpesvirus-8. Curr Opin Oncol 9(5):440-9, 1997. e-Pub 1997. PMID: 9327222.

Editorials

1. Cheng, I, Wheeler, SB, Gillison, M, Iasonos, A, Bhatia, S. Expanding Research in Cancer Epidemiology in Journal of Clinical Oncology. Journal of Clinical Oncology 42(7):765-768, 2024. PMID: 38271643.
2. Gillison, M. Flashback Foreword. Journal of Clinical Oncology 41(24):3963-3964, 2023. PMID: 37586208.
3. Gillison, M. Flashback Foreword. Journal of Clinical Oncology 41(17):3079-3080, 2023. PMID: 37285652.
4. Ferris R, Gillison ML. Nivolumab for Squamous-Cell Cancer of Head and Neck. N Engl J Med 376(6):596, 2017. PMID: 28177863.
5. Gillison ML. Human Papillomavirus and Oropharyngeal Cancer Stage. J Clin Oncol 34(16):1833-5, 2016. PMID: 27114590.
6. Rollison DE, Gillison ML. The Alpha, Beta, Gammas of Oral Human Papillomavirus Infection and Head and Neck Cancer Risk. JAMA Oncol. PMID: 26797496.
7. Yom SS, Gillison ML, Trotti AM. Dose De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer: First Tracks on Powder. Int J Radiat Oncol Biol Phys 93(5):986-8, 2015. PMID: 26581136.
8. Fakhry C, Yom S, Gillison ML. Elective versus Therapeutic Neck Dissection in Oral Cancer. N Engl J Med 373(25):2476, 2015. PMID: 26672855.
9. Gillison M. HPV and its effect on head and neck cancer prognosis. Clin Adv Hematol Oncol 8(10):680-2, 2010. PMID: 21317864.
10. Hudgins PA, Gillison M. Second branchial cleft cyst: not!!. AJNR Am J Neuroradiol 30(9):1628-9, 2009. PMID: 19556351.
11. Gillison ML. HPV and prognosis for patients with oropharynx cancer. Eur J Cancer 45 Suppl 1:383-5, 2009. PMID: 19775640.
12. Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet 363(9420):1488-9, 2004. PMID: 15135592.
13. Lowy DR, Gillison ML. A new link between Fanconi anemia and human papillomavirus-associated malignancies. J Natl Cancer Inst 95(22):1648-50, 2003. PMID: 14625250.

Abstracts

1. Gillison ML, Williams M, Johnson J, Leung CH, Reddy J, Garden AS, Ferrarotto R, Mott F, Le X, Gunn G, Lee A, Fuller C, Lu C, Moreno A, Hutcheson K, Gross N, Lango M, Goepfert R, Myers J, Hanna E, Xiao W, Jiang B, Rudqvist N, Lee JJ, Phan J. Phase 2 trial of induction and concomitant CTLA4 (ipilimumab) and PD-1 (nivolumab) immune checkpoint blockade and intensity modulated radiation therapy (IMRT) in HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC). 2022 SITC Annual Meeting:abstract 568, 2022. e-Pub 2022.
2. Gillison ML, Ferris RL, Harris J, Dimitrios Colevas A, Mell LK, Kong C, Jordan R, Moore K, M-T T, Kirsch C, Clump D, Ohr J, He, K, Blakaj DM, Deeken J, m M, Curran W, Q-T L. Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504. 2019 ASCO Annual Meeting:abstract 6073, 2019. e-Pub 2019.
3. Saba NF, Blumenschein GR, Guigay J, Licitra LF, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Lynch ML, Li L, Brossart P. Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 6028), 2018. e-Pub 2018.
4. Ferris RL, Gillison ML, Harris J, Colevas AD, Mell LK, Kong C, Jordan R, Moore K, Truong MT, Kirsch C, Clump DA, Ohr J, He K, Blakaj D, Deeken JF, Machtay M, Curran WJ, Q-T L. Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 6010, 2018. e-Pub 2018.
5. Wise-Draper TM, Old MO, Worden FP, O'Brien PE, Cohen EEW, Dunlap N, Mierzwa ML, Casper K, Palackdharry S, Hinrichs B, Molinolo A, Takiar V, Mark J, Tang A, Riaz MK, Morris JC, Sadraei NH, Xie C, Gillison ML. Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 6017), 2018. e-Pub 2018.
6. Ferris RL, Blumenschein Jr GR, Fayette J, Guigay J, Colevas A, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, LIglesias Docampo L, Raddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Nivolumab (Nivo) vs investigator’s choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141. AACR Annual Meeting 2018:abstr CT116, 2018. e-Pub 2018.
7. Gleber-Netto FO, Rao X, Erikson K, Akagi K, Johnson FM, Wang J, Califano J, Gillison ML, Myers JN, Pickering CR. "Risk stratification and biomarker discovery in HPV-positive oropharynx squamous cell carcinoma determined by HPV and human gene expression profile associations". AACR Annual Meeting 2018:abstr 4621, 2018. e-Pub 2018.
8. Concha-Benavente F, Gillison ML, Blumenschein GR, Harrington K, Fayette J, Colevas AD, Licitra L, Kasper S, Even C, Worden FP, Saba NF, Haddad RI, Tahara M, Hasegawa Y, C-J Y, Lynch MJ, Monga M, Geese WJ, Vokes EE, Ferris RL. "Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN)". 2017 ASCO Annual Meeting. Poster Session. J Clin Oncol 35, 2017 (suppl; abstr 6050), 2017. e-Pub 2017.
9. Gillison ML, Ferris RL, Zhang Q, Colevas AD, Mell LK, Kong C, Jordan R, Moore K, Truong MT, Kirsch C, Machtay M, Curran WJ, Q-T L. "A randomized phase II study of chemoradiation (CRT) +/- nivolumab (Nivo) with sequential safety evaluations of Nivo +/- lirilumab (Liri) or ipilumumab (Ipi) concomitant with (C) RT in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593)". 2017 ASCO Annual Meeting. Poster Session. J Clin Oncol 35(15_suppl):abstr TPS6097, 2017. e-Pub 2017.
10. Gillison ML, Broutian T, Graubard B, Pickard R, Z-Y T, Xiao W, Kahle L, Chaturvedi A. "Impact of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the U.S.". 2017 ASCO Annual Meeting. Oral Session. J Clin Oncol 35(15_suppl):abst 6003, 2017. e-Pub 2017.
11. Ferris RL, Licitra L, Fayette J, Even C, Blumenschein GR, Harrington K, Guigay J, Vokes EE, Saba NF, Haddad RI, Ramkumar S, Russell J, Brossart P, Tahara M, Monga M, Zhu J, Colevas AD, Gillison ML. "Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use". 2017 ASCO Annual Meeting. Poster Discussion Session. J Clin Oncol 35(15_suppl):abstr 6020, 2017. e-Pub 2017.
12. Gillison ML, Blumenschein GR, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden FR, Saba NF, Docampo LCI, Haddad RI, Rordorf T, Kiyota N, Tahara M, Lynch MJ, Kopit J, Ferris RL. "Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy". 2017 ASCO Annual Meeting. Poster Discussion Session. J Clin Oncol 35(15_suppl):abstr 6019, 2017. e-Pub 2017.
13. Symer DE, Akagi K, Coombes KR, Xiao W, Pickard RKL, Agrawal A, Gillison ML. "Comprehensive genomic analysis of human papillomavirus-associated oral cancers" [abstract]. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 76(14 Suppl):abstr 132, 2016. e-Pub 2016.
14. Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Schactman Kopit MJ, Shaw JW, Ferris RL. "Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141" [abstract]. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 76(14 Suppl):abstr CT099, 2016. e-Pub 2016.
15. Li S, Ferris RL, Holsinger FC, Weinstein GS, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Wagner LI, Ringash J, Lewin JS, Mendez E, Ridge JA, Richmon J, Magnuson S, Bell RB, Smith RB, Thomas G, Burtness B. "E3311 trial of transoral surgery for oropharynx cancer: Implementation of a novel surgeon credentialing and quality assurance process". 2016 ASCO Annual Meeting. Poster Session. J Clin Oncol 34(15_suppl):abstr 6054, 2016. e-Pub 2016.
16. Ferris RL, Blumenschein GR, Fayette J, Guigay J, Colevas AD, Licitra LF, Harrington KJ, Kasper S, Vokes EE, Even C, Worden FP, Haddad RI, Kiyota N, Tahara M, Monga M, Lynch MJ, Geese WJ, Kopit J, Shaw JW, Gillison ML. "Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141". 2016 ASCO Annual Meeting. J Clin Oncol 34(15_suppl):abstr 6009, 2016. e-Pub 2016.
17. Seiwert TY, Weiss J, Baxi SS, M-J A, Fayette J, Gillison ML, Machiels J-P H, Takahashi S, Melillo G, Franks A, Emeribe U, Raben D, McDevitt M, Psyrri A. "A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL". 2016 ASCO Annual Meeting. Poster Session. J Clin Oncol 34(15_suppl):abstr TPS6101, 2016. e-Pub 2016.
18. Fakhry C, Zhang Q, Gillison ML, Nguyen PD, Rosenthal DI, Weber RS, Lambert L, Trotti A, Barrett W, Thorstad W, Yom SS, Wong SJ, Ridge JA, Rao SS, Bonner JA, Vigneault E, Raben D, Harris J, Q-T L. "Predicting overall survival (OS) and progression-free (PFS) for oropharynx cancers (OPC) in NRG Oncology RTOG0129/0522 with nomograms". 2016 ASCO Annual Meeting. Poster Discussion Session. J Clin Oncol 34(15_suppl):abstr 6024, 2016. e-Pub 2016.
19. Cmelak A, Li S, Marur S, Zhao W, Westra WH, Chung CH, Gillison ML, Gilbert J, Bauman JE, Wagner LI, Ferris RL, Trevarthen DR, Murphy BA, Galloway T, Burtness B. "Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS V2)". 2015 ASCO Annual Meeting. Poster Discussion Session. J Clin Oncol 33(15_suppl):abstr 6021, 2015. e-Pub 2015.
20. Rettig EM, Wentz A, Posner MR, Gross ND, Haddad RI, Gillison ML, Quon H, Sikora AG, Stott W, Lorch JH, Gourin CG, Miles B, Richmon J, Misiukiewicz K, Chung CH, Fakhry C, D'Souza G. "Prognostic Implication of Persistent HPV16 DNA Detection in Oral Rinses for HPV-Positive Oropharyngeal Carcinoma". 2015 ASCO Annual Meeting. Oral Session. J Clin Oncol 33(15_suppl):abstr 6005, 2015. e-Pub 2015.
21. Marur S, Wang H, Quon H, Chung CH, Gillison ML, Agrawal N, Richmon J, Subramaniam RM, Koch W, Gourin CG, Forastiere AA. "A phase I (Ph1) study of dasatinib (D) with cetuximab (Cet) /radiation (IMRT) +/- cisplatin (P) in stage II, III/IV head and neck squamous cell carcinoma (HNSCC)". 2015 ASCO Annual Meeting. J Clin Oncol 33(15_suppl):abstr e17036, 2015. e-Pub 2015.
22. Cmelak A, Li S, Marur S, Zhao W, Westra WH, Chung CH, Gillison ML, Gilbert J, Bauman JE, Wagner LI, Ferris RL, Trevarthen DR, Colevas AD, Jahagirdar BN, Burtness B. "E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC)". 2014 ASCO Annual Meeting. Oral Session. J Clin Oncol 32(18_suppl):abstr LBA6006, 2014. e-Pub 2014.
23. Savvides P, Kumar P, Gillison ML, Teknos T. "A phase I/II clinical trial of sorafenib in combination with cisplatin and docetaxel in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN)". 2014 ASCO Annual Meeting. Poster Session. J Clin Oncol 32(15_suppl):abstr TPS6103, 2014. e-Pub 2014.
24. Marur S, Li S, Cmelak A, Gillison ML, Ferris RL, Bauman JE, Zhao W, Westra WH, Chung CH, Wagner LI, Trevarthen DR, Jahagirdar BN, Colevas AD, Burtness B, Oncology Group EC. "E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC)". 2013 ASCO Annual Meeting. Oral Session. J Clin Oncol 31(15_suppl):abstr 6005, 2013. e-Pub 2013.
25. Chung CH, Zhang Q, Kong C, Harris J, Ang KK, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan R, Q-T L. "p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC)". 2013 ASCO Annual Meeting. Oral Session. J Clin Oncol 31(15_suppl):abstr 6007, 2013. e-Pub 2013.
26. D'Souza G, Gross ND, Pai SI, Haddad RI, Gillison ML, Posner MR. "Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses". 2013 ASCO Annual Meeting. Poster Discussion Session. J Clin Oncol 31(15_suppl):abstr CRA6031, 2013. e-Pub 2013.
27. Marur S, J-W L, Cmelak A, Zhao W, Westra WH, Chung CH, Gillison ML, Gilbert J, Bauman JE, Wagner LI, Ferris RL, Trevarthen DR, Colevas AD, Jahagirdar BN, Burtness B, Oncology Group EC. "ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP)". 2012 ASCO Annual Meeting. Poster Session. J Clin Oncol 30(15_suppl):abstr 5566, 2012. e-Pub 2012.
28. Wuthrick EJ, Zhang Q, Machtay M, Ang KK, Rosenthal DI, Nguyen-Tan F, Fortin A, Silverman CI, Raben A, Kim H, Horwitz EM, Read NE, Harris J, Wu Q, Gillison ML, Oncology Group RT. "The influence of institutional head and neck cancer (HNC) clinical trial accrual on overall survival (OS): An analysis of RTOG 0129". 2012 ASCO Annual Meeting. Poster Discussion Session. J Clin Oncol 30(15_suppl):abstr 5530, 2012. e-Pub 2012.
29. Gillison ML, Jordan R, Lingen M, Perez-Ordonez B, He X, Pickard R, Inman A, Koluder M, Jiang B, Wakely P, Xiao W. "Predictive value of human papillomavirus (HPV) 16 in situ hybridization (ISH) and p16 immunohistochemistry (IHC) for HPV oncogene expression in paraffin-embedded oropharynx squamous cell carcinoma (OPSCC)". 2011 ASCO Annual Meeting. Poster Discussion Session. J Clin Oncol 29(15_suppl):abstr 5512, 2011. e-Pub 2011.
30. Ang KK, Zhang QE, Rosenthal DI, Nguyen-Tan P, Sherman EJ, Weber RS, Galvin JM, Schwartz DL, El-Naggar AK, Gillison ML, Jordan R, List MA, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. "A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC)". 2011 ASCO Annual Meeting. Oral Session. J Clin Oncol 29(15_suppl):abstr 5500, 2011. e-Pub 2011.
31. Chaturvedi A, Engels E, Pfeiffer R, Hernandez BY, Xiao W, Kim, Jiang EB, Goodman M, Sibug-Saber M, Cozen W, Liu L, Lynch C, Wentzensen N, Jordan R, Altekruse S, Anderson WF, Rosenberg P, Gillison ML. "Human papillomavirus (HPV) and rising oropharyngeal cancer incidence and survival in the United States". 2011 ASCO Annual Meeting. Poster Discussion Session. J Clin Oncol 29(15_suppl):abstr 5529, 2011. e-Pub 2011.
32. Gillison ML, Zhang Q, Ang K, Fu KK, Hammond ME, Jordan R, Trotti A, Spencer S, Rotman M, Chung CH. "Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003". 2010 ASCO Annual Meeting. J Clin Oncol 28(15_suppl):abstr 5510, 2010. e-Pub 2010.
33. Koshiol J, Rotunno M, Gillison ML, L-J VD, Tarantini L, Song H, Quint W, Struijk L, Goldstein A, Chaturvedi A, Hildesheim A, Taylor P, Wacholder S, Bertazzi PA, Landi MT, Caporaso N. "Little evidence of human papillomavirus in lung tumor tissue" [abstract]. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 70(8 Suppl):abstr 4824, 2010. e-Pub 2010.

Book Chapters

1. Jr LJ, Bishop JA, Gillison M, Westra WH, Yarborough WG. Tumours of the nasal cavity, paranasal sinuses and skull base: carcinomas: sinonasal undifferentiated carcinoma. In: WHO classification of head and neck tumours. IARC, 18–20, 2017.
2. Chaturvedi A, Gillison ML. Human papillomavirus and head and neck cancer. In: Epidemiology, Pathogenesis, and Prevention of Head and Neck Cancer. Springer Science+Business Media, LLC, 87-116, 2010.
3. Gillison ML. Human papillomavirus and the prevention and therapy of head and neck squamous cell carcinoma. In: Head and Neck Cancer. A Multidisciplinary Approach. 3rd. Lippincott Williams & Wilkins, 906-917, 2009.
4. Gillison ML. Molecular epidemiology of Human Papillomavirus Infection. In: Human Cancer Viruses: Principles of Transformation and Pathogenesis. Transl Res Biomed. Basel, Karger, 1-19, 2008.
5. Gillison ML. The Role of Chemotherapy in the Management of Squamous Cell Carcinoma of the Oral Cavity. In: Oral Cancer Diagnosis, Management, and Rehabilitation. Thieme Medical Publishers, 2007.
6. D’Souza G, Gillison ML. Head and Neck Squamous Cell Cancers. In: Squamous Cell Head and Neck Cancer. Recent Clinical Progress and Prospects for the Future. Human Press, 1-26, 2005.
7. Forastiere AA, Gillison ML. Organ Preservation in Head and Neck Cancer. In: Head and Neck Cancers: Emerging Perspectives. Academic Press, An imprint of Elsevier Science, 475-90, 2003.
8. Gillison ML, Shah KV. Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. In: J Natl Cancer Inst Monogr. 31, 57-65, 2003.
9. Gillison ML, Forastiere A. Chemotherapy of Head and Neck Carcinoma. In: Cancer Treatment. 5th, 1030‐43, 2001.
10. Gillison ML. In: Evidence for a Causal Association between Human Papillomavirus and a Subset of Head and Neck Cancers. Doctoral Thesis. The Johns Hopkins University, 2001.

Patents

1. IND # BB 11713: Sponsor-Investigator for pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA for a clinical protocol entitled "An open-label phase one study of the safety with stage III or IV HPV16-positive head and neck squamous cell carcinoma. Patent Number: 0000.